REFERENCES
- Ferreira A. Biochemical markers of bone turnover in the diagnosis of renal osteodystrophy: what do we have, what do we need?. Nephrol Dial Transplant 1998; 3(13 supp)29–32
- Drüeke T B. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 1995; 48: 259–272
- Geoffrey A B, Tempie E, Hulbert S, Nathan W L, Friedrich K. Association of serum phosphorus and calcium x phosphate. Product with mortallity risk in chronic hemodialysis patients; A National Study. Am J Kidney Dis 1998; 31(4)607–617
- Hruska K A. Renal osteodystrophy. Baillieres Clin Endocrinol Metab 1997; 11: 165–194
- Goodman W G, Veldhuis J D, Belin T R, Juppner H, Salusky I B. Suppressive effect of calcium on parathyroid hormone releaser in adynamic renal osteodystrophy and secondary hyperparathyroidism. Kidney Int 1997; 51: 1590–1595
- Hsu C H. Are we mismanaging calcium and phosphate metabolism in renal failure. Am J Kidney Dis 1997; 29(4)641–649
- Hory B, Drüeke T B. The parathyroid bone axis in uremia: new insights into old questions. Cur Opin Nephrol Hypertens 1997; 6: 40–48
- Nagaba Y, Heishi M, Tazawa H, Tsukamoto Y, Kobayashi Y. Vitamin D receptor gene polymorphisms affect secondary hyperparathyroidism in hemodialyzed patients. Am J Kidney Dis 1998; 32: 464–469
- Caravaca F, Cubero J, Jimenez F, Lopewz A, Aparicio M, Cid L, Pisarro J, Liso S I. Effect of the mode of calcitriol administration on PTH ionized calcium relationship in uraemic patient with secondary hyperparathyroidism. Nephrol Dial Transplant 1995; 10: 665–670
- Fournier A E, Arnaud C D, Johnson W J, Taylor W F, Goldsmith R S. Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. II Factors affecting serum immunoreactive parathyroid hormone. J Clin Invest 1971; 50: 599–605
- Goldsmith R S, Furszyfer J, Johnson W J, Fournier A E, Arnaud C D. Control of secondary hyperparathyroidism during long-term hemodialysis. Am J Med 1971; 50: 692–699
- Cannella G. Left ventricular hypertrophy in the dialysed patient. What can be done about it?. Nephrol Dial Transplant 1996; 11(3)418–420
- Drüeke T B. Anomalies of phosphate and calcium metabolism in chronic renal insufficiency. Rev Prat 1998; 48(11)1207–1212
- Facchin L, Vescovo G, Levedianos G, Zannini L, Nordion M, Llorenzi S, Caturelli G, Ambrosio G B. Left ventricular morphology and diastolic function in uremia echocardiographic evidence of a specific cardiomyopathy. Br Heart J 1995; 74(2)174–179
- Rao D S, Shih M S, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. New Engl J Med 1993; 328(3)171–175
- Argiles A, Mourad G, Lorho R, Kerr P G, Flavier J L, Canaud B, Mion C M. Medical treatment of severe hyperparathyreoidism and its influence on anaemia in end stage renal failure. Nephrol Dial Transplant 1994; 9(2)1809–1812
- Masoero G, Bruno M, Gallo L, Colaferro S, Cosseddu D, Vacha G M. Increased serum pancreatic enzymes in uremia: relation with treatment modality and pancreatic involvement. Pancreas 1996; 13(4)350–355
- Massry S G. Pathogenesis of uremic toxicity. Parathyroid hormone as a uremic toxin. Textbook of Nephrology, S G Massry, R J Glassock, M D Baltimore. Williams Wilkins. 1995; 1270–1303
- Balon B P, Kavalar R. Brown tumor in association with secondary hyperparathyroidism. Am J Nephrol 1998; 18: 460–463